Serum creatinine/cystatin C ratio
12 papers study it16 more mention it18 findings
- Humans12
Effects
2Hospital-associated complications
no changein humans1
1 study
Hospital-associated complications
no changein humans1
Serum creatinine/cystatin C ratio has no effect on hospital-associated complications in humans.
“no significant association was found between CCR and the incidence of HAC.”
Humanshospitalizationn = 231
Geriatrics & gerontology international
Mortality
no changein humans1
1 study
Mortality
no changein humans1
Serum creatinine/cystatin C ratio has no effect on mortality in humans.
“However, Cr/CysC*100, AST/ALT, and NLR were not associated with either overall or 30-day mortality risk.”
Humanschronic heart failuren = 482
BMC geriatrics
Associations
12Mortality
downin humans2upin humans1HR 0.4–1.59
3 studies
Mortality
downin humans2upin humans1HR 0.4–1.59
Serum creatinine/cystatin C ratio lowers the risk of mortality in humans (HR = 0.47, 95% CI: 0.31-0.69, p < 0.001).
“Cox regression revealed a negative association between Cr/CysC and all-cause mortality in the overall population (HR = 0.47, 95% CI: 0.31-0.69, p < 0.001)”
Humansin the overall population
Frontiers in nutrition
Serum creatinine/cystatin C ratio lowers the risk of mortality in humans (HR 0.40, 95% CI 0.34-0.47).
“hazard ratios comparing the highest vs. lowest quartile of Cr/CysC ratio were 0.40 (95% CI, 0.34-0.47; P < 0.001) for all-cause mortality”
Humanshighest vs. lowest quartilemedian follow-up of 17.9 yearsn = 12,914
BMC geriatrics
Serum creatinine/cystatin C ratio predicts mortality in humans (HR 1.59, 95% CI 1.12-2.24).
“lowest Cr/CysC (HR, 1.59; 95% CI, 1.12-2.24, P = 0.009) were independent factors of all-cause mortality”
Humansover 4 yearsn = 486
Heliyon
Cardiovascular mortality
downin humans2HR 0.54–0.68
2 studies
Cardiovascular mortality
downin humans2HR 0.54–0.68
Serum creatinine/cystatin C ratio lowers the risk of cardiovascular mortality in humans (HR 0.68, 95% CI 0.52-0.88).
“0.68 (95% CI, 0.52-0.88; P < 0.001) for cardiovascular mortality”
Humanshighest vs. lowest quartilemedian follow-up of 17.9 yearsn = 12,914
BMC geriatrics
Serum creatinine/cystatin C ratio lowers the risk of cardiovascular mortality in humans (adjusted HR 0.54, 95% CI 0.46-0.65).
“A higher Cr/CysC ratio was associated with a decreasing risk of CVD mortality (adjusted HR: 0.54, 95% CI: 0.46-0.65, p < 0.001, per SD increase).”
Humansmedian follow-up of 16.9 yearsn = 11,150
Reviews in cardiovascular medicine
Handgrip strength
upin humans2
2 studies
Handgrip strength
upin humans2
Serum creatinine/cystatin C ratio is associated with handgrip strength in humans (β = 0.21, 0.13, and 0.19 for the 70s, 80s, and 90s, respectively).
“The relationship between CCR and sarcopenia components was significant for handgrip strength”
HumansCommunity-dwelling Japanese older adults; adjusted analysesn = 955
Geriatrics & gerontology international
Serum creatinine/cystatin C ratio is associated with handgrip strength in humans (R2 = 0.19, P < 0.001).
“The Cr/CysC level was positively correlated with CC (R2 = 0.17, P < 0.001) and HGS (R2 = 0.19, P < 0.001).”
Humansn = 486
Heliyon
Insulin resistance
downin humans1OR 0.48
1 study
Insulin resistance
downin humans1OR 0.48
Serum creatinine/cystatin C ratio lowers the risk of insulin resistance in humans (OR = 0.48, 95% CI: 0.32-0.73, p = 0.001).
“Higher Cr/CysC ratios were strongly associated with lower IR risk (OR = 0.48, 95% CI: 0.32-0.73, p = 0.001)”
Humans
Frontiers in nutrition
Disability
downin humans1OR 0.69
1 study
Disability
downin humans1OR 0.69
Serum creatinine/cystatin C ratio lowers the risk of disability in humans (OR = 0.69, 95% CI 0.52-0.91).
“and ADL disability (SI: OR = 0.71, 95% CI 0.54-0.94; CCR: OR = 0.69, 95% CI 0.52-0.91) compared to those in the lowest quartile.”
Humanshighest vs lowest quartilen = 2,357
The journal of nutrition, health & aging
Frailty
downin humans1OR 0.24
1 study
Frailty
downin humans1OR 0.24
Serum creatinine/cystatin C ratio lowers the risk of frailty in humans (OR = 0.24, 95% CI 0.11-0.51).
“Participants in the highest quartile of SI or CCR had reduced odds of incident frailty (SI: OR = 0.24, 95% CI 0.11-0.52; CCR: OR = 0.24, 95% CI 0.11-0.51)”
Humanshighest vs lowest quartilen = 2,574
The journal of nutrition, health & aging
Cardiometabolic multimorbidity
downin humans1OR 0.89
1 study
Cardiometabolic multimorbidity
downin humans1OR 0.89
Serum creatinine/cystatin C ratio lowers the risk of cardiometabolic multimorbidity in humans (OR = 0.89, 95% CI: 0.87-0.91, p < 0.001).
“compared to the lower quartile (Q1) of SCR/CysC, the highest quartile (Q4) was associated with a decreased risk of CMM (CHARLS: odds ratio (OR) = 0.89, 95% confidence interval (CI): 0.87-0.91, p < 0.001”
HumansCHARLS database
Journal of diabetes research
Cancer mortality
downin humans1HR 0.51
1 study
Cancer mortality
downin humans1HR 0.51
Serum creatinine/cystatin C ratio lowers the risk of cancer mortality in humans (HR 0.51, 95% CI 0.36-0.71).
“0.51 (95% CI, 0.36-0.71; P < 0.001) for cancer mortality”
Humanshighest vs. lowest quartilemedian follow-up of 17.9 yearsn = 12,914
BMC geriatrics
Skeletal muscle mass index
upin humans1
1 study
Skeletal muscle mass index
upin humans1
Serum creatinine/cystatin C ratio is associated with skeletal muscle mass index in humans (β = 0.14; P = 0.0022, only for the 90s).
“however, it was limited for SMI (β = 0.14; P = 0.0022, only for the 90s)”
HumansCommunity-dwelling Japanese older adults; adjusted analysesskeletal musclen = 284
Geriatrics & gerontology international
Cardiovascular disease
downin humans1OR 0.65
1 study
Cardiovascular disease
downin humans1OR 0.65
Serum creatinine/cystatin C ratio lowers the risk of cardiovascular disease in humans (OR 0.65, 95% CI 0.52-0.81).
“the Cr/CysC ratio was inversely linked to CVD morbidity (odds ratio: 0.65, 95% CI: 0.52-0.81, p < 0.001, per standard deviation [SD] increase).”
Humansn = 11,150
Reviews in cardiovascular medicine